SCOTUS rules unanimously in favor of Sanofi and Regeneron in PCSK9 patent spat with Amgen

Zachary Brennan

Senior Editor

In a closely fought patent battle between PCSK9 rivals Amgen and Sanofi/Regeneron, the Supreme Court ruled unanimously on Thursday that Amgen cannot monopolize the market for any and every antibody that binds to areas of the sweet spot of PCSK9.

The win for Sanofi and Regeneron is a setback for companies like Amgen who are looking to patent broad categories of antibodies, but cannot produce each of the antibodies that might fall into such a category.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

TRENDING NOW

SCOTUS rules unanimously in favor of Sanofi and Regeneron in PCSK9 patent spat with Amgen

Zachary Brennan

Senior Editor

To read Endpoints News become a free subscriber

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

After gene therapy deaths, Astellas to revisit fatal neuromuscular condition in partnership with biotech startup

Upstream Bio matches first funding round with another $200M to get asthma drug to PhIII

FDA commissioner says drug prices are too high, calls for better evidence generation

4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

SCO­TUS rules unan­i­mous­ly in fa­vor of Sanofi and Re­gen­eron in PC­SK9 patent spat with Am­gen

Zachary Brennan

Senior Editor

To read Endpoints News become a free subscriber

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

Af­ter gene ther­a­py deaths, Astel­las to re­vis­it fa­tal neu­ro­mus­cu­lar con­di­tion in part­ner­ship with biotech start­up

Up­stream Bio match­es first fund­ing round with an­oth­er $200M to get asth­ma drug to PhI­II

FDA com­mis­sion­er says drug prices are too high, calls for bet­ter ev­i­dence gen­er­a­tion

4DMT's in­hal­able gene ther­a­py for cys­tic fi­bro­sis shows ear­ly pos­i­tive signs in tiny group of pa­tients

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

SCOTUS rules unanimously in favor of Sanofi and Regeneron in PCSK9 patent spat with Amgen

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

After gene therapy deaths, Astellas to revisit fatal neuromuscular condition in partnership with biotech startup

Upstream Bio matches first funding round with another $200M to get asthma drug to PhIII

FDA commissioner says drug prices are too high, calls for better evidence generation

4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape